NHS Framework Agreement for Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies for the Treatment of Cancer (Lots 1, 2, 3, 4 and 5)

A Contract Award Notice
by NHS ENGLAND

Source
Contracts Finder
Type
Framework (Services)
Duration
4 year
Value
£608M
Sector
HEALTH
Published
03 Apr 2024
Delivery
01 Apr 2024 to 31 Mar 2028
Deadline
01 Dec 2023 13:00

Concepts

Location

Geochart for 1 buyers and 6 suppliers

1 buyer

6 suppliers

Description

NHS Framework Agreement for Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies for the Treatment of Cancer (Lots 1, 2, 3, 4 and 5) Tender Reference: CM/PHR/22/5686/01 Period of framework agreement: 1 April 2024 to 31 March 2028 (covering regions East of England, London, North of England and South East).

Award Detail

1 Ith Pharma (London)
  • Value: £608,000,000
2 Qualasept (Corsham)
  • Value: £608,000,000
3 Sciensus Pharma Services (Burton on Trent)
  • Value: £608,000,000
4 Baxter Healthcare (Thetford)
  • Value: £608,000,000
5 Lloydspharmacy Clinical Homecare (Coventry)
  • Value: £608,000,000
6 Quantum Pharmaceutical (Burnopfield)
  • Value: £608,000,000

CPV Codes

  • 33600000 - Pharmaceutical products

Indicators

  • Contract is suitable for SMEs.

Other Information

Parties Appointed to the Framework Agreement - CM-PHR-22-5686 Parties Appointed to the Framework Agreement - CM-PHR-22-5686.docx 2023S 000-031801 - FTS OPPORTUNITY NOTICE - CM-PHR-22-5686 2023S 000-031801 - FTS OPPORTUNITY NOTICE - CM-PHR-22-5686.pdf Document No. 09 - Participating Authorities - CM-PHR-22-5686 Document No. 09 - Participating Authorities - CM-PHR-22-5686.xls Document No. 03 - Framework Agreement and Terms and Conditions - CM-PHR-22-5686 Document No. 03 - Framework Agreement and Terms and Conditions - CM-PHR-22-5686.docx CM-PHR-22-5686 Transparency Award Schedule (Redacted) CM-PHR-22-5686 Transparency Award Schedule (Redacted).pdf

Reference

Domains